Laurus Labs invests in Galenvs Sciences for majority ownership

Hyderabad-based Laurus Labs has announced signing of a definite agreement for investments into Galenvs Sciences for a majority ownership, a Montréal, Québec, Canada-based biotechnology company specialising in precision magnetic nanoparticles and DNA/RNA technologies for advanced diagnostics and therapeutics.

This marks an important step in Laurus Labs’ strategy to strengthen its capabilities in oligonucleotide development and manufacturing, while enhancing its Contract Development and Manufacturing Organization (CDMO) offerings.

The strategic investment is aimed at unlocking greater efficiency, scalability and technological capabilities in RNA and oligonucleotide manufacturing, enabling Laurus Labs to expand its presence in the rapidly growing field of DNA/RNA-based precision therapeutics. The combination of Galenvs Sciences’ specialised technology platforms with Laurus Labs’ research, development and manufacturing capabilities is expected to create differentiated solutions for customers developing complex and next-generation therapeutics.

The signing of a definitive Term sheet Agreement on 29th October 2026, under which Laurus Labs Ltd. acquiring 60% of the equity share capital, at a pre money valuation of $3.5 million subject to due diligence. Laurus Labs propose to invest $3.75 million, which includes a primary infusion of $2.75 million.